The metabolic driver of hair loss that nobody is testing for.
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
0:00
|
6:47
From Root to Ritual by Laritelle Organic.
The standard hair loss investigation covers hormones, ferritin, thyroid, and vitamin D. It almost never covers fasting insulin or HOMA-IR — the markers that reveal whether the body's metabolic regulation is amplifying every androgenic hair loss driver simultaneously. Recent clinical data in 2026 confirms that insulin resistance and hair loss are deeply interconnected, with the root cause of thinni...
Read the full article: https://laritelleorganic.com/blogs/news/the-metabolic-driver-of-hair-loss-that-nobody-is-testing-for
SPEAKER_00
The standard hair loss investigation covers hormones, ferritin, thyroid, and vitamin D. It almost never covers fasting insulin or HOMA IR, the markers that reveal whether the body's metabolic regulation is amplifying every androgenic hair loss driver simultaneously. Recent clinical data in 2026 confirms that insulin resistance and hair loss are deeply interconnected, with the root cause of thinning hair often lying within metabolic health rather than just the scalp. This is not a fringe observation, the mechanism is specific, documented, and runs directly through the same pathways this series has mapped as central to AJA DHT conversion, sex hormone binding globulin, and systemic inflammation. When the body's cells stop responding appropriately to insulin, the pancreas compensates by producing more. This hyperinsulinemia, chronically elevated insulin, does three things to hair biology simultaneously. It amplifies 5-alpha reductus activity, more DHT conversion. It reduces sex hormone binding globulin, more free testosterone available for conversion, and it drives the systemic low-grade inflammation that feeds the paleaf environment, the 2026 research found in 81% of AGA patients. Insulin resistance is not a diabetes problem. For the follicle, it is a DHT amplification and inflammation problem. The three mechanisms. How insulin reaches the hair follicle through three simultaneous pathways. 5 alpha reductus amplification, the DHT accelerator 5 alpha reductase is the enzyme that converts testosterone to DHT, the primary androgenic driver of follicle miniaturization. Elevated insulin upregulates 5-alpha reductus activity, increasing the rate at which testosterone is converted to DHT throughout the body, including in the scalp. This means that a woman with normal testosterone levels but elevated insulin may have DHT activity equivalent to someone with elevated testosterone because the conversion enzyme is running faster. Blocking 5-alpha reductus with phenasteride or botanical inhibitors, bringarage, saw palmetto, nettle, while leaving insulin-driven upregulation unaddressed is treating the downstream effect while the upstream driver continues. SHBG suppression, releasing free androgens, sex hormone binding globulin, SHBG, is the protein that binds testosterone and DHT in circulation, keeping them biologically inactive. Elevated insulin suppresses hepatic SHBG production, reducing the amount of testosterone that is bound and therefore raising the proportion of free testosterone available for DHT conversion. A woman with normal total testosterone but suppressed SHBG has more active androgen exposure at the follicle than her total testosterone level would suggest. This is why a standard hormonal panel that measures total testosterone but not SHBG and free testosterone misses insulin-driven androgen excess. The number that matters is free androgen index, the ratio of total testosterone to SHBG, and it requires both measurements to CA. Liculate, systemic inflammation, the PLIF amplifier. Chronic hyperinsulinemia promotes systemic low-grade inflammation through multiple pathways, increased NFKB activation, elevated inflammatory cytokines, and the pro-inflammatory adipokine production associated with insulin-resistant adipose tissue. This is the same inflammatory environment that the PI LIF research described as operating invisibly in 81% of AGA patients, damaging the upper follicle stem cell niche and progressively constraining follicle response to growth signals. Insulin resistance and PLIF are not independent processes, they share a common inflammatory substrate. Addressing metabolic health is addressing the upstream driver of the follicular inflammation that pylif describes at the tissue level. Follicle nutrient starvation, the vascular component, chronic hyperinsulinemia contributes to endothelial dysfunction, reducing the ability of blood vessels to dilate appropriately and deliver nutrients to peripheral tissues, including the scalp. High insulin levels trigger a hormonal cascade that starves hair follicles of nutrients and oxygen. This connects directly to the HIF-1A oxygen sensor mechanism we covered earlier this month. Insulin-driven endothelial dysfunction reduces follicle oxygen delivery, stressing the HIF-1A system, and shifting follicle metabolism toward the less efficient glycolytic pathway that PP405 is designed to correct. 2026-year clinical data confirmed insulin resistance DEEP, ally interconnected with hair loss, metabolic health as a root cause, not just a risk factor. PCOS affects 8-13% of women. Insulin resistance plus androgen excess creates a combined hair loss driver that neither treatment alone fully addresses SHBG. The missing marker on most standard panels, low SHBG is a more sensitive indicator of androgen excess than elevated total testosterone alone. PCOS, the most common combined driver. Why polycystic ovary syndrome is uniquely relevant to hair loss. Polycystic ovary syndrome affects approximately 8-13% of women of reproductive age and is the most common endocrine disorder in this population. PCOS combines insulin resistance with androgen excess, both of the mechanisms described above operating simultaneously, compounded by the fact that insulin resistance in PCOS directly drives the androgen excess rather than simply amplifying it. In PCOS, elevated insulin stimulates the ovarian theka cells to produce excess androgen, primarily testosterone, while simultaneously suppressing SHBG, increasing the proportion of that testosterone available for DHT conversion, and upregulating 5α reductase to accelerate that conversion. The result is a threefold amplification of DHT exposure that is entirely mediated by insulin, not by genetic 5 alpha reductus sensitivity alone. Hair loss in PCOS is frequently misidentified as standard AGA and treated with DHT blocking interventions that address the downstream effect while the insulin driven up stir.